In a strong validation of the company’s clinical trial, Imugene Ltd’s Phase 1b trial for its azer-cel off-the-shelf, allogeneic, CD19 CAR T therapy in relapsed/refractory diffuse large B-cell lymphoma ...

Inc. (Market cap: $34.46M) has reported its financial performance for the fourth quarter of 2023, highlighting a steady cash flow and strategic advancements in its clinical pipeline. According to ...

A non-profit partnered with Boardman Junior High School to help those fighting cancer. It’s called a “Blessed Bag,” and it ...

Growing up in the Black church, Kyra March was surrounded by love – and big, beautiful hats – the inspiration for an exhibit ...

Clairey Grubbs, 49, is a recovering addict who struggles with the side effects of attention deficit hyperactivity disorder, ...

HER2-positive (HER2+) breast cancer treatments come with a range of unpleasant side effects. However, there are strategies ...

Shares of solid tumor concern Zymeworks Inc. have barely budged since the company obtained its first approval. Click here to read why ZYME stock is a Hold.

Delcath Systems markets Hepzato Kit for the treatment of uveal melanoma with unresectable hepatic metastases. Click here to read my analysis of DCTH stock.